权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Elucidating the Role of Trop2 in Prostate Cancer

阐明 Trop2 在前列腺癌中的作用

基本信息

批准号：
10380825
负责人：
Tanya I Stoyanova
金额：
$ 36.41万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-04-01 至 2022-12-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10380825
关键词：
Advanced Development Aggressive Clinical Course Androgens Automobile Driving Binding Cancer Etiology Carcinoma Castration Cell Surface Proteins Cell surface Cells Cessation of life ChIP-seq Complex Development Disease Extracellular Domain Future Generations Genetic Transcription Glycoproteins Goals Growth Human Incidence Knock-out Life Expectancy Link Longevity Maintenance Malignant Neoplasms Malignant neoplasm of prostate Metastatic Prostate Cancer Molecular Neoplasm Metastasis Neurosecretory Systems Oncogenic Outcome Pathway interactions Patients Phenotype Pre-Clinical Model Proteins Receptor Activation Relapse Research Resistance Role Signal Transduction Study Section Testing United States advanced disease advanced prostate cancer androgen deprivation therapy castration resistant prostate cancer hormone therapy in vivo in vivo evaluation inhibitor insight men migration mortality novel novel therapeutic intervention overexpression prostate cancer cell prostate cancer model prostate cancer progression prostate carcinogenesis receptor response therapeutic target therapy resistant transcription factor transcriptome sequencing tumor tumor growth tumorigenesis

项目摘要

PROJECT SUMMARY/ABSTRACT Prostate cancer is the second most common cancer in men in the United States. The first line of treatment for men with aggressive prostate cancer is hormone therapy or androgen ablation therapy. Although initial responses are observed, unfortunately, the disease commonly recurs in its aggressive hormone therapy- resistant form also known as castration resistant prostate cancer (CRPC). Current therapies for hormone therapy resistant prostate cancer or CRPC prolong the patients’ lifespan by only a few months. Thus, there is an urgent need to identify the molecular mechanisms underlying the development of CRPC in order to define new strategies to overcome aggressive prostate cancer. Trop2 is a cell surface protein that is found altered in multiple types of human cancers. Our recent studies demonstrate that Trop2 is a novel promising therapeutic target for aggressive prostate cancer due to its high expression in advanced prostate cancer and its oncogenic role in the disease. The goals of the proposed research are to: 1) Establish Trop2 activation as a driver of CRPC and assess its role in tumor maintenance. 2) Investigate the molecular mechanisms through which Trop2 contributes to the development of the aggressive disease. The completion of the proposed project will lead to defining new molecular mechanisms underlying the development of aggressive prostate cancer. The proposed project will evaluate the oncogenic role of Trop2 receptor and its activation in aggressive prostate cancer in pre-clinical models of prostate cancer creating an important translational link between the proposed research and treatment of patients with aggressive disease in the near future. Due to the high expression of Trop2 in many epithelial cancers, we believe that our findings will be applicable to a broad range of cancers.

项目总结/文摘